Table 2.
Clinical and Biochemical Status by Treatment Group
| Dichotomous Clinical Endpoints | 12 Months, n (%) |
P Valuea | |
|---|---|---|---|
| LAGB | Why WAIT | ||
| n | 18 | 22 | |
| Primary Endpoint | |||
| HbA1c < 47.5 mmol/mol and FPG < 7.0 mmol/L (HbA1c < 6.5% and FPG < 126 mg/dL) | 6 (33) | 5 (23) | .457 |
| Meeting ADA treatment goals | |||
| HbA1c < 53.0 mmol/mol (<7.0%) | 10 (56) | 11 (50) | .726 |
| LDL-cholesterol < 2.59 mmol/L (<100 mg/dL) | 15 (83) | 10 (45) | .019 |
| Systolic blood pressure < 130 mm Hg | 9 (50) | 17 (77) | .078 |
| Meeting all three goals | 4 (22) | 3 (14) | .765 |
| Normoglycemia | |||
| HbA1c < 42.1 mmol/mol (<6.0%) | 5 (28) | 2 (9) | .260 |
| FPG < 5.55 mmol/L (<100 mg/dL) | 9 (50) | 9 (41) | .566 |
| Meeting both criteria | 4 (22) | 1 (5) | .231 |
Abbreviation: FPG, fasting plasma glucose; ADA, American Diabetes Association.
a
P values for differences between treatment groups from logistic regression (or exact logistic regression for cell counts less than 5).